European Agency Outlines Pediatric Drug Development Plan
The European Medicines Agency (EMA) has released a Paediatric Investigation Plan (PIP) for sargramostim. This plan details the necessary steps to develop the medicine for use in children. The initiative ensures that comprehensive data is collected to support future authorization for pediatric populations.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.